Tarsus is developing its lead candidate TP-03, potentially the first FDA-approved therapy for Demodex blepharitis, and a pipeline of investigational therapies targeting eye care, dermatology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results